Heribert Schunkert, MD: Ticagrelor vs. Aspirin in Patients Undergoing Coronary Bypass Surgery

Heribert Schunkert, MD, of the German Heart Center in Munich, Germany, talks with DocWire News about the TiCAB trial results that he presented at the American Heart Association 2018 Scientific Sessions in Chicago.

Researchers for the Ticagrelor versus Aspirin in Patients Undergoing Coronary Bypass Surgery (TiCAB) trial, seeking to clarify the balance between bleeding and thrombotic risks with antiplatelet treatment strategy in coronary artery bypass graft (CABG) patients, randomly assigned patients scheduled for CABG (1:1) to receive either 100 mg aspirin once daily or ticagrelor 90 mg twice daily. The primary study outcome was a composite of cardiovascular death, myocardial infarction, repeat revascularization, and stroke at one year post-CABG. The primary safety endpoint was major bleeding.

To read the results, see DocWire News’ coverage of the trial at AHA 2018.

Eric Raible is editor of the Cardiology section of DocWire News and has more than a decade’s worth of experience in covering and publishing in the cardiology space. Eric has previously served as a founding editor of CardioSource WorldNews, and is a former staff writer and editor of Cardiology Today.